Use of the angiotensin-(1-9) peptide or derivatives thereof, use of vectors overexpressing the ACE2 enzyme that produces angiotensin-(1-9) for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation

Patent metadata

Field	Value
Publication number	US-9511120-B2
Application number	US-201214390663-A
Country	US
Kind code	B2
Filing date	Apr 5, 2012
Priority date	Apr 5, 2012
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

The present invention is related to the use of the angiotensin-(1-9) peptide or peptides derived therefrom, which are biological or chemical analogs, for preparing medicaments useful for preventing, reverting, inhibiting and/or reducing hypertension and/or inducing vasodilation. Furthermore, this invention also comprises a vector overexpressing the homologous angiotensin-II converting enzyme (ACE2) for elevating the concentration in the blood and/or tissues of the angiotensin-(1-9) peptide. This vector may be adenovirus, retrovirus, lentivirus or adeno-associated virus containing the gene encoding for ACE2. This invention allows the administration of angiotensin-(1-9) or the derivatives thereof in oral form, injectable form, continuous infusion pump, or for increasing its levels in the body by means of the combined treatment with angiotensin-I converting enzyme inhibitors, with angiotensin-II receptor antagonists (ARA II), with Rho kinase inhibitors, with renin inhibitors, with L-type calcium channel antagonists and/or with diuretics.

First claim

The invention claimed is:

1. A method of treating hypertension, which comprises administering an effective amount to a patient in need thereof angiotensin-(1-9) peptide.

2. A method of inducing vasodilation, which comprises administering an effective amount to a patient in need thereof angiotensin-(1-9).

3. The method according to claim 1 , further comprising preventing, reverting, inhibiting and/or reducing cardiovascular, renal, pulmonary, cerebral damage caused by hypertension.

4. The method according to claim 1 , wherein said angiotensin-(1-9) peptide is in a pharmaceutical injectable form.

5. The method according to claim 1 , wherein the angiotensin-(1-9) peptide is administered in a form that is released continuously inside the body.

6. The method according to claim 1 wherein the angiotensin-(1-9) peptide is administered with a continuous release pump.

7. The method according to claim 5 , wherein said continuous release is carried out via intravenous, intramuscular, intradermal, subcutaneous, or intraperitoneal route.

8. The method according to claim 1 , wherein said angiotensin-(1-9) peptide is in oral or rectal pharmaceutical form.

9. The method according to claim 1 , which comprises overexpressing the homologous angiotensin-I converting enzyme (ACE2).

10. The method according to claim 9 , wherein the overexpression of the homologous angiotensin-I converting enzyme (ACE2) is obtained by adenovirus, adeno-associated virus, retrovirus, lentivirus.

11. A method of treating hypertension, which comprises administering to a patient in need thereof angiotensin-(1-9) peptide and at least one pharmaceutical compound selected from angiotensin-I converting enzyme inhibitors, angiotensin-II receptor antagonists (ARA II), Rho kinase inhibitors, renin inhibitors, L-type calcium channel antagonists and diuretics.

12. The method according to claim 2 , wherein said wherein said angiotensin-(1-9) is in a pharmaceutical injectable form.

13. The method according to claim 2 , wherein the angiotensin-(1-9) peptide or derivatives of said peptide is administered in a form that is released continuously inside the body.

14. The method according to claim 13 , wherein the angiotensin-(1-9) peptide is administered with through a continuous release pump.

15. The method according to claim 4 , wherein the angiotensin-(1-9) peptide is administered with through a continuous release pump.

16. The method according to claim 5 , wherein the angiotensin-(1-9) peptide is administered with through a continuous release pump.

17. The method according to claim 13 , wherein said continuous release is carried out via intravenous, intramuscular, intradermal, subcutaneous, or intraperitoneal route.

18. The method according to claim 14 , wherein said continuous release is carried out via intravenous, intramuscular, intradermal, subcutaneous, or intraperitoneal route.

19. The method according to claim 5 , wherein said continuous release is carried out via intravenous, intramuscular, intradermal, subcutaneous, or intraperitoneal route.

20. The method according to claim 2 , wherein the angiotensin-(1-9) peptide is in oral or rectal pharmaceutical form.

21. The method according to claim 1 , wherein said angiotensin-(1-9) peptide is administered with an adjuvant.

22. The method according to claim 1 , wherein said angiotensin-(1-9) peptide is administered with a preservative.

23. The method according to claim 2 , wherein said angiotensin-(1-9) peptide is administered with an adjuvant.

24. The method according to claim 2 , wherein said angiotensin-(1-9) peptide is administered with a preservative.

Assignees

• Ocaranza Jeraldino Maria Paz
• Jalil Milad Jorge Emilio
• Lavandero González Sergio Alejandro
• Chiong Lay Mario Martin
• Michea Acevedo Luis Fernando
• Pontifica Univ Católica De Chile
• Univ Chile

Inventors

• Ocaranza Jeraldino Maria Paz
• Jalil Milad Jorge Emilio
• Lavandero González Sergio Alejandro
• Chiong Lay Mario Martin
• Michea Acevedo Luis Fernando

Classifications

• A61K38/553

  Renin inhibitors · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/085

  Angiotensins · CPC title

• A61K38/556

  Angiotensin converting enzyme inhibitors · CPC title

• A61K38/4813

  Exopeptidases (3.4.11. to 3.4.19) · CPC title